Section 119402 Of Chapter 8. Drug Marketing Practices From California Health And Safety Code >> Division 104. >> Part 15. >> Chapter 8.
119402
. (a) Every pharmaceutical company shall adopt a
Comprehensive Compliance Program that is in accordance with the April
2003 publication "Compliance Program Guidance for Pharmaceutical
Manufacturers," which was developed by the United States Department
of Health and Human Services Office of Inspector General (OIG). A
pharmaceutical company shall make conforming changes to its
Comprehensive Compliance Program within six months of any update or
revision to the "Compliance Program Guidance for Pharmaceutical
Manufacturers."
(b) Every pharmaceutical company shall include in its
Comprehensive Compliance Program policies for compliance with the
Pharmaceutical Research and Manufacturers of America (PhRMA) "Code on
Interactions with Health Care Professionals," dated July 1, 2002.
The pharmaceutical company shall make conforming changes to its
Comprehensive Compliance Program within six months of any update or
revision of the "Code on Interactions with Health Care Professionals."